Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kinfemichael, Gedif"'
Autor:
Ramin Tadayoni, Glenn J. Jaffe, Frank G. Holz, Ursula Schmidt-Erfurth, Kanji Takahashi, Chui Ming Gemmy Cheung, Seenu M. Hariprasad, Kinfemichael Gedif, Rasmus Olsen, Catherine Best, Franklin Igwe, Peter K. Kaiser
Publikováno v:
Ophthalmology and Therapy, Vol 12, Iss 4, Pp 2209-2216 (2023)
Abstract Introduction The HAWK and HARRIER studies evaluated the efficacy and safety of brolucizumab versus aflibercept in treatment-naïve eyes with neovascular age-related macular degeneration. Based on the study design, brolucizumab-treated eyes a
Externí odkaz:
https://doaj.org/article/7fdc7736c96b45888e4698c7d337b076
Autor:
Stephen H. Poor, Georges Weissgerber, Christopher M. Adams, Harit Bhatt, David J. Browning, James Chastain, Thomas A. Ciulla, Michael Ferriere, Kinfemichael Gedif, Louis C. Glazer, Brian C. Joondeph, Guillaume Normand, Veeral Sheth, Christie Watters, Cynthia L. Grosskreutz
Publikováno v:
American Journal of Ophthalmology. 239:180-189
To evaluate whether topical acrizanib (LHA510), a small-molecule vascular endothelial growth factor receptor inhibitor, could suppress the need for anti-vascular endothelial growth factor therapy over a 12-week period in patients with neovascular age
Autor:
David R. Lally, Anat Loewenstein, Jennifer J. Arnold, Yit C. Yang, Kinfemichael Gedif, Catherine Best, Hersh Patel, Ramin Tadayoni, Jeffrey S. Heier
Publikováno v:
Eye. 37:1242-1248
Objective Post-hoc analysis to compare the outcomes of brolucizumab 6 mg vs. aflibercept 2 mg in neovascular age-related macular degeneration (nAMD) patients with early persistent retinal fluid in HAWK and HARRIER. Methods After 3 monthly loading dos
Autor:
Arshad M. Khanani, Kinfemichael Gedif, Chirag Jhaveri, Michael C. Singer, Charles C. Wykoff, Guruprasad B, Andrew Chang, Chiara M. Eandi
Publikováno v:
American Journal of Ophthalmology. 236:12-19
Purpose Determine associations between early residual fluid (ERF)-free status and improved long-term visual outcomes. Design Clinical cohort study from post hoc analysis of two phase 3 clinical trials’ data. Methods Independent of treatment allocat
Autor:
Luis Abrishamian, Marc Bonten, Richa Chandra, Damodaran Solai Elango, Pierre Fustier, Kinfemichael Gedif, Susana Goncalves, Awawu Igbinadolor, Jeff Kingsley, Charles G Knutson, Petra Kukkaro, Nagalingeswaran Kumarasamy, Philippe Legenne, Martha Mekebeb-Reuter, Krishnan Ramanathan, Evgeniya Reshetnyak, Michael Robinson, Jennifer Rosa, Marianne Soergel, Vaia Stavropoulou, Nina Stojcheva, Michael T Stumpp, Andreas Tietz, Xiaojun Zhao, Zhaojie Zhang
Publikováno v:
Open Forum Infectious Diseases. 9
Background Ensovibep is a multi-specific DARPin (designed ankyrin repeat protein) antiviral in clinical development for treatment of COVID-19. In the Phase 2 EMPATHY study, ensovibep demonstrated greater viral load decline versus placebo. Here we rep
Autor:
Kinfemichael Gedif, William R. Schucany, Wayne A Woodward, Patrick S. Carmack, Robert W. Haley
Publikováno v:
Journal of Data Science. 10:403-418
Various statistical models have been proposed to analyze fMRI data. The usual goal is to make inferences about the eects that are related to an external stimulus. The primary focus of this paper is on those statisti- cal methods that enable one to de
Autor:
Ursula Schmidt-Erfurth, Rishi P Singh, Georges Weissgerber, Adrian Koh, Frank G. Holz, Pravin U. Dugel, Kinfemichael Gedif, Yuichiro Ogura, Glenn J. Jaffe, Ramin Tadayoni
Publikováno v:
Ophthalmology. 128:89-99
Purpose To report the 96-week outcomes from HAWK and HARRIER. Design Phase 3, prospective, randomized, double-masked, multicenter studies comparing efficacy and safety of brolucizumab 3 mg (HAWK only) and 6 mg with aflibercept 2 mg in eyes with neova
Autor:
Michael Singer, Arshad M. Khanani, Armin Wolf, Rita Flores, Jay Chhablani, Guruprasad B, Andreas Clemens, Kinfemichael Gedif, Xiaoxi Liu, Zufar Mulyukov, Giuseppe Querques
Publikováno v:
Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde. 245(4)
Introduction: This post hoc analysis applies a fixed dosing stratification approach to patient-level brolucizumab data from the phase III HAWK and HARRIER trials to determine the proportion of patients who would have been assigned to fixed dosing reg
Autor:
David R, Lally, Anat, Loewenstein, Jennifer J, Arnold, Yit C, Yang, Kinfemichael, Gedif, Catherine, Best, Hersh, Patel, Ramin, Tadayoni, Jeffrey S, Heier
Publikováno v:
Eye (London, England).
Post-hoc analysis to compare the outcomes of brolucizumab 6 mg vs. aflibercept 2 mg in neovascular age-related macular degeneration (nAMD) patients with early persistent retinal fluid in HAWK and HARRIER.After 3 monthly loading doses, brolucizumab-tr
Autor:
Rishi P. Singh, Chirag Jhaveri, Charles C. Wykoff, Richard P. Gale, Giovanni Staurenghi, Tomohiro Iida, Adrian Koh, Guruprasad B, Kinfemichael Gedif, Michael Singer
Publikováno v:
Ophthalmology. Retina. 6(5)
To compare the outcomes of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration with early residual fluid in the HAWK and HARRIER studies.Post hoc analysis using pooled data from the phase 3 studies HAWK (NCT0